about
The treatment landscape in thyroid cancer: a focus on cabozantinibManagement of anaplastic thyroid cancerRadiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapyCancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival RatesTreatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?Radiotherapy in anaplastic thyroid carcinoma: An Australian experience.Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case reportReal-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.Use of vemurafenib in anaplastic thyroid carcinoma: a case reportImpact of Timeliness of Resection and Thyroidectomy Margin Status on Survival for Patients with Anaplastic Thyroid Cancer: An Analysis of 335 Cases.Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy.Clinical decision making in cancer care: a review of current and future roles of patient age.Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study.
P2860
Q26796404-B96D0459-1C91-4A9E-87A8-0685D47A762DQ28080836-518C08EE-BED2-403E-809C-790FFFAA8393Q31151565-08A7CCD1-874B-45C4-8372-68D8FE7B433BQ33840202-680106C2-A142-45C6-86E0-2B55A534C61AQ35869025-82C56F85-7359-45AA-9371-E1561402B2A2Q38217116-955B868E-B174-4B85-962B-158084DBBC44Q38848568-61F91166-1E52-415E-A16D-3E300E777764Q38886490-25984931-E618-4FF5-B211-5A13C47CF074Q38971872-D227D353-7DAE-44DB-879A-A83CD375310AQ39244943-51725A44-D5B1-404B-ACAD-858D509D2DF3Q40657693-46321A51-5380-4D41-8AD0-38882DBCDE33Q41485082-F31A9E68-2D3C-4D3C-95FB-26C665B4B141Q42680715-46218BFF-B30F-4C79-8F51-AF1D193D9E14Q47631967-4200A123-CDEF-43F0-8D20-1286D15644D9Q55135907-68FE64BA-1004-4E91-9DBC-7FC1FDD5E7E4Q55406601-E2DB9D82-0CF4-4157-8E37-D09029BBDB71
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Marginal treatment benefit in anaplastic thyroid cancer
@ast
Marginal treatment benefit in anaplastic thyroid cancer
@en
type
label
Marginal treatment benefit in anaplastic thyroid cancer
@ast
Marginal treatment benefit in anaplastic thyroid cancer
@en
prefLabel
Marginal treatment benefit in anaplastic thyroid cancer
@ast
Marginal treatment benefit in anaplastic thyroid cancer
@en
P2093
P2860
P356
P1433
P1476
Marginal treatment benefit in anaplastic thyroid cancer
@en
P2093
Francis Worden
Huiying Yin
Jennifer J Griggs
Megan R Haymart
Mousumi Banerjee
P2860
P304
P356
10.1002/CNCR.28187
P407
P577
2013-07-09T00:00:00Z